RE-BVS – Piemonte Repository

Sfoglia per AUTORE
MANNINA D
Collezione AOU Alessandria

Items : 8

Efficacy and safety of bendamustine, rituximab and bortezomib treatment in relapsed/refractory Waldenstrom Macroglobulinaemia: results of phase 2 single-arm FIL-BRB trial. in British journal of haematology / Br J Haematol. 2025 Feb;206(2):556-564. doi: 10.1111/bjh.19920. Epub 2024 Nov 27.

2025
AOU Alessandria
AOU Città della Salute di Torino

Ferrero S; Freilone R; Varettoni M; Tani M; Merli M; Sartori R; Musuraca G; Tosi P; Pietrantuono G; Mannina D; Caravita di Toritto T; Ferrante M; Gaidano G; Rossi FG; Conconi A; Dessi D; Califano C; Curreli L; Cavallo F; Boccomini C; Monaco F; Villivà N; Castiglione A; Drandi D; Benevolo G;

End of induction [(18)F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial. in European journal of nuclear medicine and molecular imaging / Eur J Nucl Med Mol Imaging. 2024 Sep;51(11):3311-3321. doi: 10.1007/s00259-024-06765-z. Epub 2024 Ma

2024
AOU Alessandria
AO Cuneo

Usai SV; Vitolo U; Falcinelli F; Gini G; Galimberti S; Roti G; Mannina D; Musto P; Conconi A; Massaia M; Bari A; Califano C; Arcari A; Chiarenza A; Pavone V; Bolis SAM; Bianchi B; Tosi P; Musuraca G; Ladetto M; Barbieri E; Monaco L; Franceschetto A; Peano S; Durmo R; Marcheselli L; Bergesio F; Fallanca F; Chauvie S; et alii...

Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial. in The Lancet. Haematology / Lancet Haematol. 2024 Jul;11(7):e499-e509. doi: 10.1016/S2352-3026(24)00143-1.

2024
AOU Alessandria
AOU Città della Salute di Torino

Della Starza I; Drandi D; Genuardi E; Ciabatti E; Bomben R; De Novi LA; Cavalli M; Guarini A; Grapulin L; Assanto GM; Annechini G; Tani M; Celli M; Mannina D; Mannarella C; Cencini E; Re F; Bigliardi S; Corradini P; Stelitano C; Tucci A; Perrone T; Gaidano G; Musuraca G; Bernuzzi P; Bolis SA; Zilioli VR; Rattotti S; Ferreri AJM; et alii...

High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study. in Haematologica / Haematologica. 2023 Aug 1;108(8):2091-2100. doi: 10.3324/haematol.2022.282116.

2023
AOU Alessandria
AO Cuneo
AO Ordine Mauriziano
AOU Città della Salute di Torino

Fazi P; Vignetti M; Guarini A; Cuneo A; Piciocchi A; De Propris MS; Nanni M; Del Giudice I; Neri A; De Novi LA; Albano F; Vitale C; Visentin A; Pietrasanta D; Mattiello V; Molinari MC; Liberati AM; Giordano A; Patrizi VB; Gottardi D; Galieni P; Deodato M; Arcari A; Musuraca G; Tani M; Levato L; Marchetti M; Massaia M; Rigolin GM; et alii...

Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2022 Mar 1;40(7):729-739. doi: 10.1200/JCO.21.01234. Epub 2021 Oct 28.

2022
AOU Alessandria
AO Cuneo
AOU Città della Salute di Torino

Anastasia A; Dondi A; Mannina D; Federico M; Chiarenza A; Arcari A; Zilioli VR; Merli A; Ladetto M; Bolis S; Pavone V; Pinto A; Margiotta Casaluci G; Patti C; Stelitano C; Ricci F; Del Giudice I; Chauvie S; Kovalchuk S; Skrypets T; Cavallo F; Ferrero S; Arcaini L; Farina L; Olivieri J; Marcheselli L; Tucci A; Boccomini C; Guerra L; et alii...

Safety and Efficacy of Subcutaneous Rituximab in Previously Untreated Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Results from an Italian Phase IIIb Study. in Advances in hematology / Adv Hematol. 2022 Jan 27;2022:5581772. doi: 10.1155/2022/5581772. eCollection 2022.

2022
AOU Alessandria

Petrini M; Gaidano G; Mengarelli A; Consoli U; Santoro A; Liberati AM; Ladetto M; Fraticelli V; Guarini A; Mannina D; Ferrando P; Corradini P; Musto P; Stelitano C; Marino D; Camera A; Murineddu M; Battistini R; Caparrotti G; Turrini M; Arcaini L; Santini S; Cerqueti M; Ferreri AJM; Cantore N; Inzoli A; Cardinale G; Ronci B; La Nasa G; et alii...

Application of the Euro Clonality next-generation sequencing-based marker screening approach to detect immunoglobulin heavy chain rearrangements in mantle cell lymphoma patients: first data from the Fondazione Italiana Linfomi MCL0208 trial. in British journal of haematology / Br J Haematol. 2021 Jul;194(2):378-381. doi: 10.1111/bjh.17519. Epub 2021 May 18.

2021
AOU Alessandria
AOU Città della Salute di Torino

Cordero F; Calogero RA; Ferrero S; Cortelazzo S; Ladetto M; Rota Scalabrini D; Califano C; Mannina D; Alessandria B; Romano G; Beccuti M; Genuardi E;

Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study. in Cancers / Cancers (Basel). 2021 Dec 31;14(1):207. doi: 10.3390/cancers14010207.

2021
AOU Alessandria
AO Ordine Mauriziano
AOU Città della Salute di Torino

Cuneo A; Foà R; Piciocchi A; Rigolin GM; Guarini A; Neri A; Fazi P; Raponi S; Nanni M; Della Starza I; De Propris MS; Del Giudice I; Ruocco V; Varettoni M; Ibatici A; Murru R; Laurenti L; Gentile M; Chiarenza A; Gozzetti A; Molinari A; Zinzani PL; Gottardi D; Musuraca G; Tani M; Orsucci L; Re F; Liberati AM; Ilariucci F; et alii...